Arvinas Stock News

Arvinas Inc (NASDAQ: ARVN) announced the presentation of new data from completed Phase 1 dose-escalation and ongoing Phase 2 ARDENT expansion cohort with bavdegalutamide (ARV-110). The data were sh

– Bavdegalutamide demonstrated a 46% PSA50 rate in patients with metastatic castration-resistant prostate cancer (mCRPC) and androgen receptor (AR) T878X/H875Y tumor mutations –

Upgrades According to Gordon Haskett, the prior rating for Williams-Sonoma Inc (NYSE:WSM) was changed from Hold to Accumulate. Williams-Sonoma earned $3.32 in the third quarter, compared to $2.56 in t

These underappreciated opportunities in healthcare are worth a closer look.

ARVN is doing superb, interesting science. If successful, this company could become a game-changer. They have some upcoming catalysts.

NEW HAVEN, Conn., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today an

NEW HAVEN, Conn., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it will participate in two upcoming virtual investor conferences:

NEW HAVEN, Conn., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today anno

Goldman Sachs has launched its coverage on platform biotech companies issuing Buy recommendations for Arvinas <> and Arrowhead Pharmaceuticals <> with 12-month price targets…

A tough 2021 has small-cap stocks positioned for a potentially fruitful 2022. Analysts are most bullish on these 12 picks in the new year.

Arvinas Inc. (NASDAQ:ARVN) shares, rose in value on Friday, 12/17/21, with the stock price up by 6.69% to the previous days close as strong demand from buyers drove the stock to $73.40. Actively observing the price movement in the last trading, the stock closed the session at $68.80, falling within a range of $66.64 and Arvinas Inc. (NASDAQ: ARVN) Stock Could Be An Option To Consider Read More »

Arvinas, Inc. (NASDAQ:ARVN) Director Liam Ratcliffe sold 85,705 shares of the companys stock in a transaction dated Thursday, December 16th. The stock was sold at an average price of $69.36, for a total transaction of $5,944,498.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this []

Emerald Advisers LLC raised its holdings in Arvinas, Inc. (NASDAQ:ARVN) by 5.9% during the 3rd quarter, Holdings Channel reports. The firm owned 284,541 shares of the companys stock after purchasing an additional 15,779 shares during the quarter. Emerald Advisers LLCs holdings in Arvinas were worth $23,384,000 at the end of the most recent reporting period. []

Royal Bank of Canada increased its holdings in Arvinas, Inc. (NASDAQ:ARVN) by 38.3% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,989 shares of the companys stock after acquiring an additional 828 shares during the quarter. Royal Bank of Canadas holdings in Arvinas []